Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and MTD of GRN163L in Patients With Refractory or Relapsed Solid Tumor Malignancies

NCT00310895 is registered in ClinicalTrials.gov with Geron Corporation as lead sponsor.

NCT NCT00310895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00310895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and MTD of GRN163L in Patients With Refractory or Relapsed Solid Tumor Malignancies
Lead sponsor
Geron Corporation
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2006
Completion date
March 31, 2013
Enrollment
85 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor malignancies